Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Italy-based pharmaceutical company Recordati has announced that its subsidiary Bouchara Recordati has launched Zanextra, its new antihypertensive treatment, in France.
Subscribe to our email newsletter
This new specialty Zanextra is already available in Germany, Australia, Ireland, Finland, Denmark, Greece, South Africa and in the Netherlands.
Giovanni Recordati, chairman and CEO of Recordati, said: “The launch of Zanextra in France, the largest market for lercanidipine, is an important event for the growth of our group. We are confident that the excellent therapeutic characteristics of this new specialty and the quality of our French medical representatives, which has been recognized by doctors in France, will ensure the success of Zanextra.”